What were the key details of XOMA Royalty's share repurchases in H1 2026?

The Company repurchased approximately 11,000 shares at an average price of $24 per share, for a total expenditure of $264,000. The shares were retired and not held as treasury stock, with any excess cost over par value recorded to accumulated deficit.

Does this filing disclose a new or expanded buyback authorization?

No. The filing references an existing stock repurchase program executed from time to time, including in the open market, but does not announce, authorize, amend, or expand any program. No dollar or share authorization is disclosed in this 8-K/A filing.

What mechanism was used to execute these repurchases?

The filing does not specify the mechanism—whether open-market purchases under Rule 10b-18, a 10b5-1 plan, or another method. The accounting treatment simply notes repurchases were made and retired.

How significant were these repurchases relative to XOMA Royalty's overall capital deployment?

Very modest. The $264K outlay represents a small portion of the company's cash balance of $150.6 million (unrestricted cash of $99.3 million) as of June 30, 2026. The share reduction was also minimal relative to the 17.7 million shares outstanding at period end.

Are there restrictions on the company's ability to repurchase shares?

The filing does not discuss any restrictions. However, the company notes in its liquidity section that it has sufficient financial condition to fund planned operations, commitments, and contractual obligations for at least one year, suggesting capital allocation flexibility.

How does XOMA Royalty account for repurchased shares?

Per the company's stated policy, repurchased shares are retired and no treasury stock is recognized. Any excess of cost over par value is recorded to accumulated deficit. This treatment reduces issued and outstanding shares directly.

LGNYZ 8-K/A Filed 2026-09-02 Execution disclosure

XOMA Royalty repurchased 11K shares at $24 average in H1 2026

Modest execution under existing program; $264K total outlay in first half of year.

Shares repurchased11K

Avg price paid$24.00

MechanismNot specified

What the filing says

XOMA Royalty Corporation executed modest share repurchases during the first half of 2026, buying back approximately 11,000 shares at an average price of $24 per share for a total outlay of $264,000. The repurchases were reflected in the Company's condensed consolidated statement of convertible preferred stock and stockholders' equity for the six months ended June 30, 2026, and appear in the financing activities section of the cash flow statement.

The filing does not specify the mechanism for the repurchases (open market, 10b-18, ASR, or other), nor does it disclose details of any new or amended authorization. The repurchases reduced common stock shares issued and outstanding, with the excess cost over par value recorded to accumulated deficit in accordance with the Company's stated accounting policy of retiring repurchased shares.

As of June 30, 2026, XOMA Royalty had 17.7 million shares of common stock issued and outstanding, down slightly from 17.9 million at year-end 2025. The Company maintains a stock repurchase program executed through purchases made from time to time, including in the open market.

null

Repurchase of common stock totaling $264 thousand during the six months ended June 30, 2026, reducing shares issued and outstanding by 11 thousand shares at an average price of approximately $24 per share. — LIGAND PHARMACEUTICALS INC 8-K/A filing · View on SEC EDGAR →

What this means

XOMA Royalty's H1 2026 repurchase activity was minimal in absolute terms ($264K) and represents a small reduction in share count. At an average price of $24 per share, the repurchases were modest relative to the company's market position and capital deployment. The filing does not disclose authorization details, remaining capacity, or the buyback mechanism, making it difficult to assess whether this reflects a formal, board-authorized program or opportunistic purchases. With $150.6 million in cash and equivalents and restricted cash as of June 30, 2026, liquidity does not appear to be a constraint on the company's buyback capacity. The repurchase activity had minimal dilution-offset impact given the company's 17.7 million share count.

Frequently asked questions

What were the key details of XOMA Royalty's share repurchases in H1 2026?: The Company repurchased approximately 11,000 shares at an average price of $24 per share, for a total expenditure of $264,000. The shares were retired and not held as treasury stock, with any excess cost over par value recorded to accumulated deficit.
Does this filing disclose a new or expanded buyback authorization?: No. The filing references an existing stock repurchase program executed from time to time, including in the open market, but does not announce, authorize, amend, or expand any program. No dollar or share authorization is disclosed in this 8-K/A filing.
What mechanism was used to execute these repurchases?: The filing does not specify the mechanism—whether open-market purchases under Rule 10b-18, a 10b5-1 plan, or another method. The accounting treatment simply notes repurchases were made and retired.
How significant were these repurchases relative to XOMA Royalty's overall capital deployment?: Very modest. The $264K outlay represents a small portion of the company's cash balance of $150.6 million (unrestricted cash of $99.3 million) as of June 30, 2026. The share reduction was also minimal relative to the 17.7 million shares outstanding at period end.
Are there restrictions on the company's ability to repurchase shares?: The filing does not discuss any restrictions. However, the company notes in its liquidity section that it has sufficient financial condition to fund planned operations, commitments, and contractual obligations for at least one year, suggesting capital allocation flexibility.
How does XOMA Royalty account for repurchased shares?: Per the company's stated policy, repurchased shares are retired and no treasury stock is recognized. Any excess of cost over par value is recorded to accumulated deficit. This treatment reduces issued and outstanding shares directly.

execution open-market small-cap biotech-royalty h1-2026 modest-buyback

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.